FDA Endorses, Pushes for Abuse-resistant Opioid Formulations: Transition to Disrupt Pain Market

Description

FDA Endorses, Pushes for Abuse-FDA Endorses, Pushes for Abuse- resistant Opioid Formulations: Transition to Disrupt Pain Market PR Newswire MOUNTAIN VIEW, California, Dec. 17, 2013 -- Frost & Sullivan: The removal of non-TRF opioids, creates significant opportunity for innovative therapies The opioid market is dominated by non-tamper resistant formulations (TRFs), but the Food and Drug Administration's (FDA's) promotion of TRF therapies could well result in the departure of non-TRF therapies from the market and shake up its structure. Purdue Pharma's Oxycontin is the only opioid pain treatment among the top 50 selling pharmaceutical products in the U.S. Unless the FDA mandates TRF therapies, further genericization and lack of novel mechanism of actions (MOAs) will ensure opioids are unrepresented in the top 50 by 2018. Despite these debilitating trends, large opportunity remains for tamper resistant technologies, as well as combination therapies to minimize side effects from opioid products. New analysis from Frost & Sullivan's Competitive Analysis of the Global Opioid Therapeutics Market (http://www.lifesciences.frost.com), finds, with 25 million Americans suffering from moderate-to-severe chronic pain that interferes with their daily lives, orally-delivered pain products will continue to dominate the market. Purdue's Oxycontin leads this category, generating $2.77 billion in sales in 2012.

Informations

• Publié par: frost-sullivan
• Publié le: 17 décembre 2013
• Nombre de lectures: 14
• Langue: English

Extrait

FDA Endorses, Pushes for Abuse-resistant Opioid Formulations: Transition to Disrupt Pain Market

PR Newswire

MOUNTAIN VIEW, California, Dec. 17, 2013

-- Frost & Sullivan: The removal of non-TRF opioids, creates significant opportunity for innovative therapies

The opioid market is dominated by non-tamper resistant formulations (TRFs), but the Food and Drug Administration's (FDA's) promotion of TRF therapies could well result in the departure of non-TRF therapies from the market and shake up its structure.